Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
8-K
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
8 Jan 24
EFFECT
Notice of effectiveness
5 Dec 23
EFFECT
Notice of effectiveness
5 Dec 23
S-3/A
Shelf registration (amended)
30 Nov 23
CORRESP
Correspondence with SEC
30 Nov 23
CORRESP
Correspondence with SEC
30 Nov 23
UPLOAD
Letter from SEC
22 Nov 23
UPLOAD
Letter from SEC
22 Nov 23
S-3
Shelf registration
17 Nov 23
S-3
Shelf registration
17 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
BioLife Solutions Reports Third Quarter 2023 Financial Results
9 Nov 23
D
$10.37 mm in equity, sold $10.37 mm, 1 investor
27 Oct 23
8-K
BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
23 Oct 23
8-K
Entry into a Material Definitive Agreement
19 Oct 23
8-K
Regulation FD Disclosure
31 Aug 23
8-K
Departure of Directors or Certain Officers
16 Aug 23
S-8
Registration of securities for employees
16 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Results of Operations and Financial Condition
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
27 Jul 23
DEF 14A
Definitive proxy
6 Jun 23
8-K
Departure of Directors or Certain Officers
6 Jun 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
19 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
NT 10-Q
Notice of late quarterly filing
11 May 23
8-K
BioLife Solutions Reports First Quarter 2023 Financial Results
10 May 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Regulation FD Disclosure
23 Mar 23
NT 10-K
Notice of late annual filing
17 Mar 23
8-K
BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results
16 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
BioLife Solutions Reports Third Quarter 2022 Financial Results
9 Nov 22
8-K
BioLife Solutions Announces COO to Retire and Join Board of Directors
6 Oct 22
8-K
Entry into a Material Definitive Agreement
26 Sep 22
S-8
Registration of securities for employees
12 Sep 22
8-K
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
26 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Latest ownership filings
4
Troy Wichterman
25 Mar 24
4
Amy DuRoss
13 Mar 24
4
Garrie Richardson
12 Mar 24
4
Rachel Ellingson
12 Mar 24
4
Todd Berard
12 Mar 24
4
JOYDEEP GOSWAMI
12 Mar 24
4
Aby J. Mathew
12 Mar 24
4
Geraint Phillips
12 Mar 24
4
GREEF RODERICK DE
12 Mar 24
4
TIMOTHY L. MOORE
12 Mar 24
4
Troy Wichterman
12 Mar 24
4
Karen A. Foster
12 Mar 24
4
Sarah Aebersold
12 Mar 24
4
Joseph C Schick
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Sarah Aebersold
23 Feb 24
4
Troy Wichterman
23 Feb 24
4
Geraint Phillips
23 Feb 24
4
Todd Berard
23 Feb 24
4
Aby J. Mathew
23 Feb 24
4
Karen A. Foster
23 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
GOLDMAN SACHS GROUP INC
2 Feb 24
4
Sarah Aebersold
25 Jan 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
24 Jan 24
4
Karen A. Foster
23 Jan 24
4
Geraint Phillips
23 Jan 24
4
Aby J. Mathew
23 Jan 24
4
GREEF RODERICK DE
23 Jan 24
4
Troy Wichterman
23 Jan 24
4
Sarah Aebersold
23 Jan 24
4
Todd Berard
23 Jan 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Karen A. Foster
4 Jan 24
4
Todd Berard
4 Jan 24
4
Aby J. Mathew
4 Jan 24
4
Troy Wichterman
28 Dec 23
4
Karen A. Foster
21 Dec 23
4
Troy Wichterman
21 Dec 23
4
Geraint Phillips
21 Dec 23